Soluble CD25 is increased in patients with sepsis-induced acute kidney injury

Nephrology

Volumn 19, Issue 6, 2014, Pages 318-324

  Cho, Eunjung ^a   Lee, Ji Hyun ^b   Lim, Hye Jin ^b   Oh, Se Won ^b   Jo, Sang Kyung ^a   Cho, Won Yong ^a   Kim, Houng Kyu ^a   Lee, So Young ^b  

^a Korea University College of Medicine   (South Korea)

^b Eulji General Hospital   (South Korea)

Author keywords

acute kidney injury; immune suppression; sepsis; soluble CD25

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOLUBLE CD25 ANTIGEN; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ACUTE KIDNEY INJURY; BACTERIAL INFECTION; BLOOD; COMPLICATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SOLUBILITY; URINE; VERY ELDERLY;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIPOCALINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; SEPSIS; SOLUBILITY; T-LYMPHOCYTES, REGULATORY;

EID: 84901050889     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12230     Document Type: Article

References (33)

1. Bell M, Granath F, Schon S, et al. Continuous renal replacement therapy is associated with less chronic renal failure. Intensive Care Med. 2007; 33: 773-780.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294: 813-818.
3. Kox WJ, Volk T, Kox SN, Volk HD,. Immunomodulatory therapies in sepsis. Intensive Care Med. 2000; 26 (Suppl 1): S124-128.
4. Munford RS, Pugin J,. Normal response to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 2001; 163: 316-321.
5. Saito K, Wagatsuma T, Toyoma H, et al. Sepsis is characterized by the increase in percentages of circulating CD4+CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J. Exp. Med. 2008; 216: 61-68.
6. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 1999; 27: 1230-1251.
7. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 14541-14546.
8. Lee SY, Lee YS, Choi HM, et al. Distinct pathophysiologic mechanisms of septic acute kidney injury: Role of immune suppression and renal tubular cell apoptosis in murine model of septic acute kidney injury. Crit. Care Med. 2012; 40: 2997-3006.
9. Plataki M, Kashani K, Cabello-Garza J, et al. Predictors of acute kidney injury in septic shock patients: An observational cohort study. Clin. J. Am. Soc. Nephrol. 2011; 6: 1744-1751.
10. Chawla LS, Seneff MG, Nelson DR, et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin. J. Am. Soc. Nephrol. 2007; 2: 22-30.
11. Cho EJ, Cha IH, Yoon KC, et al. Clinical characteristics and outcomes of septic acute kidney injury in critically ill patients. Korean J. Nephrol. 2011; 30: 253-259.
12. Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative workgroup: Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit. Care 2004; 8: R204-R212.
13. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 2003; 31: 1250-1256.
14. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin. J. Am. Soc. Nephrol. 2007; 2: 431-439.
15. Host EJ, Lameire NH, Vanholder RC, et al. Acute renal failure in patients with sepsis in a surgical ICU: Predictive factors, incidence, comorbidity, and outcome. J. Am. Soc. Nephrol. 2003; 14: 1022-1030.
16. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S,. Renal blood flow in sepsis. Crit. Care 2005; 9: R363-374.
17. Langenberg C, Wan L, Egi M, May CN, Bellomo R,. Renal blood flow in experimental septic acute renal failure. Kidney Int. 2006; 69: 1996-2002.
18. Chvojka J, Sykora R, Krouzecky A, et al. Renal hemodynamic, microcirculatory, metabolic and histopathologic responses to peritonitis induced septic shock in pigs. Crit. Care 2008; 12: R164.
19. Langenberg C, Bagshaw SM, May CN, et al. The histopathology of septic acute kidney injury: A systemic review. Crit. Care 2008; 12: R38.
20. Hotchkiss RS, Nicholson DW,. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 2006; 6: 813-122.
21. Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am. J. Physiol. Renal. Physiol. 2007; 292: F116-122.
22. Lee WY, Koh EJ, Lee SM,. A combination of ischemic preconditioning and allopurinol protects against ischemic injury through a nitric oxide-dependent mechanism. Nitric Oxide 2012; 26: 1-8.
23. Taha MO, Simões MJ, Noguerol EC, et al. Effects of allopurinol on ischemia and reperfusion in rabbit livers. Transplant. Proc. 2009; 41: 820-823.
24. Shevach EM, Dipaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+CD25+FoxP3+ regulatory T cells. Immunol. Rev. 2006; 212: 60-73.
25. Sakaguchi S, Ono M, Setoguchi R, et al. FoxP3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006; 212: 8-27.
26. Monneret G, Debard AL, Venet F, et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit. Care Med. 2003; 31: 2068-2071.
27. Nelson BH, Willerford DM,. Biology of the interleukin-2 receptor. Adv. Immunol. 1998; 70: 1-81.
28. Pederson AE, Lauritsen JP,. CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells dose not inhibit the action of IL-2. Scand. J. Immunol. 2009; 70: 40-43.
29. Vignali DA, Collison LW, Workman CJ,. How regulatory T cells work. Nat. Rev. Immunol. 2008; 8: 523-532.
30. Hiraki S, Ono S, Tsujimoto H, et al. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival. Surgery 2012; 151: 313-322.
31. Cabrera R, Ararat M, Eksioglu A, et al. Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. Scand. J. Immunol. 2010; 72: 293-301.
32. Thurman JM, Parikh CR,. Peeking into the black box: New biomarkers for acute kidney injury. Kidney Int. 2008; 73: 463-493.
33. Vaidya V, Ferguson M, Bonventre J,. Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. 2008; 48: 463-493.